Antibody reagents are the key components of multiparametric flow cytometry analysis. Their quality performance is an absolute requirement for reproducible flow cytometry experiments. While there is an enormous body of antibody reagents available, there is still a lack of consensus about which criteria should be evaluated to select antibody reagents with the proper performance, how to validate antibody reagents for flow cytometry, and how to interpret the validation results. The achievements of cytometry moved the field to a higher number of measured parameters, large data sets, and computational data analysis approaches. These advancements pose an increased demand for antibody reagent performance quality. This review summarizes the codevelopment of cytometry, antibody development, and validation strategies. It discusses the diverse issues of the specificity, cross-reactivity, epitope, titration, and reproducibility features of antibody reagents, and this review discusses the validation principles and methods that are currently available and those that are emerging. We argue that significant efforts should be invested by antibody users, developers, manufacturers, and publishers to increase the quality and reproducibility of published studies. More validation data should be presented by all stakeholders; however, the data should be presented in sufficient experimental detail to foster reproducibility, and community effort shall lead to the public availability of large data sets that can serve as a benchmark for antibody performance. © 2019 International Society for Advancement of Cytometry.

BioLegend Inc San Diego CA USA

CLIP Childhood Leukemia Investigation Prague Department of Pediatric Hematology and Oncology 2nd Medical School Charles University and University Hospital Motol Prague Czech Republic

Department of Biomedical Sciences Faculty of Medicine and Health Sciences University of Barcelona Barcelona Spain

Zobrazit více v PubMed

Chattopadhyay PK, Hogerkorp C-M, Roederer M. A chromatic explosion: The development and future of multiparameter flow cytometry. Immunology 2008;125:441-449.

Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE, Tanner SD. Mass cytometry: Technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009;81:6813-6822.

Bendall SC, Simonds EF, Qiu P, Amir ED, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011;332:687-697.

Grégori G, Rajwa B, Patsekin V, Jones J, Furuki M, Yamamoto M, Paul RJ. Hyperspectral cytometry. Curr Top Microbiol Immunol 2014;377:191-210.

Grégori G, Patsekin V, Rajwa B, Jones J, Ragheb K, Holdman C, Robinson JP. Hyperspectral cytometry at the single-cell level using a 32-channel photodetector. Cytom Part A 2012;81A:35-44.

Chester C, Maecker HT. Algorithmic tools for mining high-dimensional cytometry data. J Immunol 2015;195:773-779.

Mair F, Hartmann FJ, Mrdjen D, Tosevski V, Krieg C, Becher B. The end of gating? An introduction to automated analysis of high dimensional cytometry data. Eur J Immunol 2016;46:34-43.

Olsen LR, Leipold MD, Pedersen CB, Maecker HT. The anatomy of single cell mass cytometry data. Cytom. Part A 2019;95A((2)):156-172.

Roncador G, Engel P, Maestre L, Anderson AP, Cordell JL, Cragg MS, Šerbec VČ, Jones M, Lisnic VJ, Kremer L, et al. The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs 2016;8:27-36.

Bordeaux J, Welsh AW, Agarwal S, Killiam E, Baquero MT, Hanna JA, Anagnostou VK, Rimm DL. Antibody validation. Biotechniques 2010;48:197-209.

Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B, Clausson C-M, Zieba A, Ramström M, Söderberg O, et al. Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun 2017;8:15840.

Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biol 2015;13:1-9.

Baker M. Reproducibility crisis: Blame it on the antibodies. Nature 2015;521:274-276.

van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, van der Velden VHJ, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908-1975.

Schmutz S, Valente M, Cumano A, Novault S. Spectral cytometry has unique properties allowing multicolor analysis of cell suspensions isolated from solid tissues. PLoS One 2016;11:1-15.

Nettey L, Giles AJ, Chattopadhyay PK. OMIP-050: A 28-color/30-parameter fluorescence flow cytometry panel to enumerate and characterize cells expressing a wide Array of immune checkpoint molecules. Cytom Part A 2018A;93:1094-1096.

Liechti T, Roederer M. OMIP-0XX - 28-color flow cytometry panel to characterize B cells and myeloid cells. Cytom. Part A 2019;95A((2):150-155.

Brodie TM, Tosevski V, Medová M. OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry. Cytom Part A 2018A;93:406-410.

Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, Böttcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonça A, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012;26:1986-2010.

Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VHJ, Novakova M, Mejstrikova E, Hrusak O, Böttcher S, Karsch D, et al. Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds. Cytom Part A 2015A;87:145-156.

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán J-J, Vidriales M-B, García-Sanz R, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 2017;31((10)):2094-2103.

Blanco E, Pérez-Andrés M, Arriba-Méndez S, Contreras-Sanfeliciano T, Criado I, Pelak O, Serra-Caetano A, Romero A, Puig N, Remesal A, et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol 2018;141:2208-2219.

Finak G. The computational article format: Software as a research output. Cytom Part A 2018A;93:1187-1188.

Conrad VK, Dubay CJ, Malek M, Brinkman RR, Koguchi Y, Redmond WL. Implementation and validation of an automated flow cytometry analysis pipeline for human immune profiling. Cytom. Part A 2019;95A((2)):183-191.

Ivison S, Brinkman RR, Levings MK, Ivison S, Malek M, Garcia RV, Broady R, Halpin A, Richaud M, Brant RF, et al. A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. JCI Insight 2018;3:121867.

Kvistborg P, Gouttefangeas C, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, et al. Thinking outside the gate: Single-cell assessments in multiple dimensions. Immunity 2015;42:591-592.

Maecker HT, JP MC, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R, Banchereau J, Boshoff C, Braun J, et al. A model for harmonizing flow cytometry in clinical trials. Nat Immunol 2010;11:975-978.

Bloomfield M, Kanderova V, Kalina T, Sediva A. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol 2018;38((5)):589-960.

Nowatzky J, Stagnar C, Manches O. OMIP-0XX identification, classification, and isolation of major FoxP3 expressing human CD4 + Treg subsets. Cytom Part A 2018;95A:1-4.

Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytom Part A 2005;67A:4-17.

O'Gorman MRG. Flow cytometry assays in primary immunodeficiency diseases. Methods Mol. Biol 2018;1678:321-345.

Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT, Richards SJ. Clinical cytometry society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom B Clin Cytom 2010;78:211-230.

Springer TA. César Milstein, the father of modern immunology. Nat Immunol 2002;3:501-503.

Bernard A, Boumsell L. The clusters of differentiation (CD) defined by the first international workshop on human leucocyte differentiation antigens. Hum Immunol 1984;11:1-10.

Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin B-Q, Malavasi F, Mortari F, Schwartz-Albiez R, et al. CD nomenclature 2015: Human leukocyte differentiation antigen workshops as a driving force in immunology. J Immunol 2015;195:4555-4563.

Pilarski LM, Deans JP. Selective expression of CD45 isoforms and of maturation antigens during human thymocyte differentiation: Observations and hypothesis. Immunol. Lett 1989;21:187-198.

Imakiire T, Kuroki MM, Shibaguchi H, Abe H, Yamauchi Y, Ueno A, Hirose Y, Yamada H, Yamashita Y, Shirakusa T, et al. Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int J Cancer 2004;108:564-570.

Michel MC, Wieland T, Tsujimoto G. How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 2009;379:385-388.

Engel P. Validation of monoclonal antibodies against leukocyte immunoglobulin-like receptors (CD85/LILR) and nomenclature. In: 9th EuroMAbNet Meet. Abstr. Pecs; 2017. p 18.

Ghosh S, Campbell AM. Multispecific monoclonal antibodies. Immunol Today 1986;7:217-222.

Lund-Johansen F, Browning MD. Should we ignore western blots when selecting antibodies for other applications? Nat Methods 2017;14:215-215.

Holm A, Wu W, Lund-Johansen F. Antibody array analysis of labelled proteomes: How should we control specificity? Nat Biotechnol 2012;29:578-585.

Slaastad H, Wu W, Goullart L, Kanderova V, Tjønnfjord G, Stuchly J, Kalina T, Holm A, Lund-Johansen F. Multiplexed immuno-precipitation with 1725 commercially available antibodies to cellular proteins. Proteomics 2011;11:4578-4582.

Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-226.

Sutherland DR, Illingworth A, Marinov I, Ortiz F, Andreasen J, Payne D, Wallace PK, Keeney M. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - Reagent selection and assay optimization for high-sensitivity testing. Cytom Part Bm 2018;94B:23-48.

Hulspas R. Titration of fluorochrome-conjugated antibodies for labeling cell surface markers on live cells. Curr Protoc Cytom 2010;54:6.29.1-6.29.9.

Kantor A, Roederer M. FACS analysis of lymphocytes. In: Herzenberg AL, Weir DM, Herzenberg LA, Blackwell C, editors. Handb. Exp. Immunol. 5th ed. Cambridge: Blackwell Science, 1997; p. 49.1-49.13.

Sutherland DR, Ortiz F, Quest G, Illingworth A, Benko M, Nayyar R, Marinov I. High-sensitivity 5-, 6-, and 7-color PNH WBC assays for both Canto II and Navios platforms. Cytom B. Clin. Cytom 2018;94:637-651.

Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, et al. A proposal for validation of antibodies. Nat Methods 2016;13:823-827.

Lin M. Cell surface antigen CD109 is a novel member of the alpha 2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 2002;99:1683-1691.

Baker M. Antibody anarchy: A call to order. Nature 2015;527:545-551.

Bürckstümmer T, Banning C, Hainzl P, Schobesberger R, Kerzendorfer C, Pauler FM, Chen D, Them N, Schischlik F, Rebsamen M, et al. A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods 2013;10:965-971.

Sikorski K, Mehta A, Inngjerdingen M, Thakor F, Kling S, Kalina T, Nyman TA, Stensland ME, Zhou W, de Souza GA, et al. A high-throughput pipeline for validation of antibodies. Nat Methods 2018;15((11)):909-912.

Lund-Johansen F, Davis K, Bishop J, de Waal Malefyt R. Flow cytometric analysis of immunoprecipitates: High-throughput analysis of protein phosphorylation and protein-protein interactions. Cytometry 2000;39:250-259.

Wu W, Slåstad H, de la Rosa CD, Frey T, Tjønnfjord G, Boretti E, Aasheim H-C, Horejsi V, Lund-Johansen F. Antibody array analysis with label-based detection and resolution of protein size. Mol Cell Proteomics 2009;8:245-257.

Stuchlý J, Kanderová V, Fišer K, Cerná D, Holm A, Wu W, Hrušák O, Lund-Johansen F, Kalina T. An automated analysis of highly complex flow cytometry-based proteomic data. Cytometry 2012;81:120-129.

Papagno L, Almeida JR, Nemes E, Autran B, Appay V. Cell permeabilization for the assessment of T lymphocyte polyfunctional capacity. J Immunol Methods 2007;328:182-188.

Law JP, Hirschkorn DF, Owen RE, Biswas HH, Norris PJ, Lanteri MC. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+ regulatory T cells. Cytom Part A 2009;75A:1040-1050.

Cossarizza A, Chang H-D, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol 2017;47:1584-1797.

Helsby MA, Fenn JR, Chalmers AD. Reporting research antibody use: How to increase experimental reproducibility. F1000Res 2013;2:153.

Helsby MA, Leader PM, Fenn JR, Gulsen T, Bryant C, Doughton G, Sharpe B, Whitley P, Caunt CJ, James K, et al. CiteAb: A searchable antibody database that ranks antibodies by the number of times they have been cited. BMC Cell Biol 2014;15:1-12.

Björling E, Uhlén M. Antibodypedia, a portal for sharing antibody and antigen validation data. Mol Cell Proteom 2008;7:2028-2037.

Spidlen J, Breuer K, Rosenberg C, Kotecha N, Brinkman RR. FlowRepository: a resource of annotated flow cytometry datasets associated with peer-reviewed publications. Cytom. Part A 2012;81A:727-731.

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J, et al. ImmPort: Disseminating data to the public for the future of immunology. Immunol. Res 2014;58:234-239.

Lee JA, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M, Furlong J, Gasparetto M, Goldberg M, Goralczyk EM, et al. International Society for Advancement of cytometry data standards task force, Scheuermann RH, Brinkman RR. MIFlowCyt: The minimum information about a flow cytometry experiment. Cytom Part A 2008;73A:926-930.

Uhlen M. Response to: Should we ignore western blots when selecting antibodies for other applications? Nat Methods 2017;14:215-216.

Mahnke YD, Roederer M. OMIP-001: Quality and phenotype of ag-responsive human T-cells. Cytom Part A 2010;77A:819-820.

Mahnke Y, Chattopadhyay P, Roederer M. Publication of optimized multicolor immunofluorescence panels. Cytom Part A 2010;77A:814-818.

Spidlen J, Breuer K, Brinkman R. Preparing a Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) Compliant Manuscript Using the International Society for Advancement of Cytometry (ISAC) FCS File Repository (FlowRepository.org). Curr Protoc Cytom 2012;61:1-26.

Clark G, Stockinger H, Balderas R, van Zelm MC, Zola H, Hart D, Engel P. Nomenclature of CD molecules from the tenth human leucocyte differentiation antigen workshop. Clin Transl Immunol 2016;5:7-9.

Standardization of Workflow and Flow Cytometry Panels for Quantitative Expression Profiling of Surface Antigens on Blood Leukocyte Subsets: An HCDM CDMaps Initiative